Treatment of Alzheimer’s disease across the spectrum of severity

References

• [AGS–AAGP] American Geriatrics Society and American Association for Geriatric Psychiatry2003Consensus statement on improving the quality of mental health care in U.S. nursing homes: Management of depression and behavioral symptoms associated with dementiaJ Am Geriatr Soc5112879812919243
   PubMed Web of Science ®Google Scholar
• AlexopoulosGJesteDCarpenterD2005Expert Consensus Guideline Series: Treatment of dementia and its behavioral disturbancesPostgraduate Medicine Special ReportMcGraw-Hill
   Google Scholar
• BallardCG2002Advances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibition (review)Eur Neurol47647011803198
   PubMed Web of Science ®Google Scholar
• BirksJSMelzerD2000Donepezil for mild and moderate Alzheimer’s diseaseCochrane Database Syst Rev4CD00119011034704
   PubMedGoogle Scholar
• BlesaRDavidsonMKurzA2003Galantamine provides sustained benefits in patients with “Advanced moderate” Alzheimer’s disease for at least 12 monthsDement Geriatr Cogn Disord15798712566596
   PubMed Web of Science ®Google Scholar
• BraneGGottfriesCGWinbladB2001The Gottfries-Brane-Steen scale: validity, reliability, and application in anti-dementia drug trialsDement Geriatr Cogn Disord1211411125236
   PubMed Web of Science ®Google Scholar
• BurnsARossorMHeckerJ1999The effects of donepezil in Alzheimer’s disease-results from a multinational trialDement Geriatr Cogn Disord102374410325453
   PubMed Web of Science ®Google Scholar
• BurnsASpiegelRQuargP2004Efficacy of rivastigmine in subjects with moderately severe Alzheimer’s diseaseInt J Geriatr Psychiatry19243915027039
   PubMed Web of Science ®Google Scholar
• Cohen-MansfieldJ2001Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critiqueAm J Geriatr Psychiatry93618111739063
   PubMed Web of Science ®Google Scholar
• Corey-BloomJAnandRVeachJ1998A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new cholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s diseaseInt Geriatr Psychopharmacol25565
   Google Scholar
• CourtneyCFarrellDGrayRAD 2000 Collaborative group2004Long term donepezil in 565 patients with Alzheimer’s disease (AD 2000): randomized double-blind trialLancet36321051515220031
   PubMed Web of Science ®Google Scholar
• CummingsJLMegaMGrayK1994The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementiaNeurology442308147991117
   PubMed Web of Science ®Google Scholar
• CummingsJL2004Alzheimer’s disease: drug therapyN Engl J Med351566715229308
   PubMed Web of Science ®Google Scholar
• DeDeynPRabheruKRasmussenA1999A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementiaNeurology539465510496251
   PubMed Web of Science ®Google Scholar
• DoodyRSStevensJCBeckC2001Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology5611546611342679
   PubMed Web of Science ®Google Scholar
• FarlowMAnandRMessinaJJr2000A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s diseaseEur Neurol2442364111096224
   PubMed Web of Science ®Google Scholar
• [FDA] Food and Drug Administration2005FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disorders [online]Accessed 1 October 2005. URL: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm
   Google Scholar
• FeldmanHGauthierSHeckerJDonepezil MSAD Study Investigators group2001A 24-week randomized, double-blind study of donepezil in moderate to severe Alzheimer’s diseaseNeurology5761320Correction in Neurology, 57:2153.11524468
   PubMed Web of Science ®Google Scholar
• FinkelSIMintzerJEDyskenM2004A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezilInt J Geriatr Psychiatry1991814716694
   PubMed Web of Science ®Google Scholar
• FolsteinMFFolsteinSEMcHughPR1975“Mini-mental state”: a practical method for grading the cognitive state of subjects for the clinicianJ Psychiatr Res12189981202204
   PubMed Web of Science ®Google Scholar
• GalaskoDBennettDSanoM1997An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s disease cooperative studyAlzheimer Dis Assoc Disord11Suppl 2S3399236950
   PubMed Web of Science ®Google Scholar
• GelinasIGauthierLMcIntyreM1999Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementiaAm J Occup Ther534718110500855
   PubMed Web of Science ®Google Scholar
• HolmesCWilkinsonDDeanC2004The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer’s diseaseNeurology632141915277611
   PubMed Web of Science ®Google Scholar
• KasckowJWMulchaheyJJMohamedS2004The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care settingJ Am Med Dir Assoc5242815228634
   PubMedGoogle Scholar
• KatzIRJesteDVMintzerJERisperidone study group1999Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trialJ Clin Psychiatry6010711510084637
   PubMed Web of Science ®Google Scholar
• KmietowiczZ2005NICE proposes to withdraw Alzheimer’s drugs from NHSBMJ33049515746112
   PubMed Web of Science ®Google Scholar
• LyketsosCGDelCampoLSteinbergM2003Treating depression in Alzheimer’s disease: efficacy and safety of sertraline therapy and the benefits of depression reduction: the DIADSArch Gen Psychiatry607374612860778
   PubMed Web of Science ®Google Scholar
• LyketsosCGReichmanWEKershawP2004Long-term outcomes of galantamine treatment in patients with Alzheimer’s diseaseAm J Geriatr Psychiatry124738215353385
   PubMed Web of Science ®Google Scholar
• LyketsosCGSteinbergMTschanzJT2000Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in agingAm J Psychiatry1577081410784462
   PubMed Web of Science ®Google Scholar
• MaelickeASamochockiMJostockR2001Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s diseaseBiol Psychiatry492798811230879
   PubMed Web of Science ®Google Scholar
• MohsRCDoodyRSMorrisJC2001A 1-year placebo-controlled preservation of function survival study of donepezil in Alzheimer’s disease patientsNeurology574818Correction in Neurology, 57:194211502917
   PubMed Web of Science ®Google Scholar
• MolloyDWAlemayehuERobertsR1991Reliability of a standardized mini-mental state examination compared with the traditional mini-mental state examinationAm J Psychiatry14810251984692
   PubMed Web of Science ®Google Scholar
• [NIMH] National Institute of Mental Health1986Clinical global impressionsGuyWECDEU assessment manual for psychopharmacologyRockville, MA21722
   Google Scholar
• OlinJSchneiderL2002Galantamine for Alzheimer’s diseaseCochrane Database Syst Rev3CD00174712137632
   PubMedGoogle Scholar
• PanissetMRoudierMSaxtonJ1994Severe Impairment battery. A neuropsychological test for severely demented patientsArch Neurol514158274108
   PubMed Web of Science ®Google Scholar
• PeskindERPotkinSGPomaraN2004Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer’s disease: a randomized, controlled trial [abstract]Eur J Neurol11Suppl 2186
   Google Scholar
• PetersonRCStevensJCGanguliM2001Practice parameter: early detection of dementia: mild cognitive impairment (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology5611334211342677
   PubMed Web of Science ®Google Scholar
• PetersenRCThomasRGGrundmanM2005Vitamin E and donepezil for the treatment of mild cognitive impairmentN Engl J Med35223798815829527
   PubMed Web of Science ®Google Scholar
• PollockBGMulsantBHRosenJ2002Comparison of citalopram, perphenazine and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patientsAm J Psychiatry159460511870012
   PubMed Web of Science ®Google Scholar
• PorteinssonAPTariotPErbR2001Placebo-controlled study of divalproex sodium for agitation in dementiaAm J Geriatr Psychiatry9586611156753
   PubMed Web of Science ®Google Scholar
• RaskindMAPeskindERWesselT2000Galantamine in Alzheimer’s disease. A 6-month randomized placebo-controlled trial with a 6-month extension. The galantamine USA-1 Study groupNeurology5422617610881250
   PubMed Web of Science ®Google Scholar
• ReissbergBDoodyRStofflerA2003Memantine in moderate to severe Alzheimer’s diseaseN Engl J Med34813334112672860
   PubMed Web of Science ®Google Scholar
• RelkinNRReichmanWEOrazemJ2003A large, community-based, open-label trial of donepezil in the treatment of Alzheimer’s diseaseDement Geriatr Cogn Disord161152412714795
   PubMed Web of Science ®Google Scholar
• RitchieCWAmesDClaytonT2004Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s diseaseAm J Geriatr Psychiatry123586915249273
   PubMed Web of Science ®Google Scholar
• RogersSLDoodyRSMohsR1998Donepezil improves cognition and global function in Alzheimer’s disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study groupArch Intern Med1581021319588436
   PubMed Web of Science ®Google Scholar
• RogersSLDoodyRSPrattRD2000Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label studyEur Neuropsychopharmacol1019520310793322
   PubMed Web of Science ®Google Scholar
• RogersSLFarlowMRDoodyRS1998A 24-week, double-blind placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study GroupNeurology50136459443470
   PubMed Web of Science ®Google Scholar
• RosenWGMohsRCDavisKL1984A new rating scale for Alzheimer’s diseaseAm J Psychiatry1411356646496779
   PubMed Web of Science ®Google Scholar
• RoslerMAnandRCicin-SainA1999Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trialBMJ318633810066203
   PubMed Web of Science ®Google Scholar
• SakauyeKMCampCJFordPA1993Effects of buspirone on agitation associated with dementiaAm J Geriatr Psychiatry1824
   PubMedGoogle Scholar
• SchneiderLSOlinJTDoodyRS1997Validity and reliability of the Alzheimer’s disease cooperative study – clinical global impression of change. The Alzheimer’s disease Co-operative StudyAlzheimer Dis Assoc Disord11Suppl2S22329236949
   PubMed Web of Science ®Google Scholar
• SeltzerBZolnouniPNunezM2004Efficacy of donepezil in early-stage Alzheimer’s disease. A randomized Placebo-controlled trialArch Neurol611852615596605
   PubMed Web of Science ®Google Scholar
• SheltonPSHockingLB1997Zolpidem for dementia-related insomnia and nighttime wanderingAnn Pharmacother31319229066939
   PubMed Web of Science ®Google Scholar
• SinkKMHoldenKFYaffeK2005Pharmacological treatment of neuropsychiatric symptoms of dementia, a review of the evidenceJAMA29359660815687315
   PubMed Web of Science ®Google Scholar
• StreetJClarkSGannonK2000Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer’s disease in nursing care facilitiesArch Gen Psychiatry579687611015815
   PubMed Web of Science ®Google Scholar
• TariotPNFarlowMRGrossbergGTMemantine Study Group2004Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil, a randomized controlled trialJAMA2913172414734594
   PubMed Web of Science ®Google Scholar
• TariotPNRosemaryRNPodgorskiCA1998Efficacy and tolerability of carbamazepine for agitation and aggression in dementiaAm J Psychiatry15554619433339
   PubMed Web of Science ®Google Scholar
• TariotPNSchneiderLKatzI2002Quetiapine in nursing home residents with Alzheimer’s dementia and psychosisAm J Geriatr Psychiatry10Suppl 193
   Google Scholar
• TariotPNSolomonPRMorrisJC2000A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer’s disease. The Galantamine USA-10 Study GroupNeurology542269227610881251
   PubMed Web of Science ®Google Scholar
• van der KamPMolFWimmersMF1971Beoordelingsschaal voor oudere patienten (BOP)Van Loghum SlaterusThe Netherlands
   Google Scholar
• WhitehousePJPriceDLStrubleRG1982Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrainScience215123797058341
   PubMed Web of Science ®Google Scholar
• WilcockGKLilienfieldSGaensE2000Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicenter randomized controlled trial. Galantamine International-1 Study GroupBMJ3211710875807
   PubMed Web of Science ®Google Scholar
• WinbladBEngedalKSoininenHDonepezil Nordic Study2001A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate Alzheimer’s diseaseNeurology574899511502918
   PubMed Web of Science ®Google Scholar
• WinbladBPoritisN1999Memantine in severe dementia: results of the M-BEST study (Benefit and efficacy in severely demented patients during treatment with memantine)Int J Geriatr Psychiatry141354610885864
   PubMed Web of Science ®Google Scholar